Maine plateaus in reduction of antipsychotic use; toolkit coming to move the needle
CMS is tracking the progress of the Partnership by reviewing publicly reported measures. As a reminder, the official measure of the Partnership is a the percent of long-stay nursing home residents who are receiving an antipsychotic medication, excluding those residents diagnosed with schizophrenia, Huntington's Disease or Tourette's Syndrome. In 2011 Q4, 23.9% of long-stay nursing home residents nationwide were receiving an antipsychotic medication; since then there has been a decrease of 38.9% to a national prevalence of 14.6% in 2018 Q3. Success has varied by state and CMS region.
The Partnership continues to work on the Dementia Care Change Package. Members may recall that this framework takes a multi-pronged approach aimed at improving dementia care and decreasing the off-label use of antipsychotics in nursing homes across the state. It includes areas like physician education, data, staff competencies, environmental factors, etc. Facilities that use the toolkit should see a reduction in A/P utilization.
The next meeting is:
Tuesday, March 26, 2019, 9:30 am at Maine Health Care Association,
317 State Street, Augusta, ME 04074, Ph: 207-623-1146
If you would like to be added to a subcommittee to work on one of the eight parts of the package, or would like to RSVP for the meeting, please contact Nadine Grosso at email@example.com.
Nadine Grosso, Vice President & Director of Communications